Lab Anim Res.
2021 Dec;37(4):307-319. 10.1186/s42826-021-00110-3.
Comparison of cisplatin-induced anti-tumor response in CT26 syngeneic tumors of three BALB/c substrains
- Affiliations
-
- 1Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources & Life Science/Life and Industry Convergence Research Institute/ Laboratory Animals Resources Center, Pusan National University, Miryang, South Korea.
- 2College of Veterinary Medicine, Kyungpook National University, Daegu, South Korea.
- 3College of Pharmacy, Pusan National University, Busan, South Korea.
- 4Exercise Biochemistry Laboratory, Korea National Sport University, Seoul, South Korea.
- 5Department of Clinical Laboratory Science, College of Nursing and Healthcare Science, Dong-Eui University, Busan, South Korea.
- 6Department of Veterinary Theriogenology, College of Veterinary Medicine, Chungbuk National University, Cheongju, South Korea.
- KMID: 2523775
- DOI: http://doi.org/10.1186/s42826-021-00110-3
Abstract
- Background
To determine whether the background of BALB/c substrains affects the response to anti-tumor drugs, we measured for alterations in tumor growth, histopathological structure of the tumor, and expressions of tumorrelated proteins in three BALB/c substrains derived from different sources (BALB/cKorl, BALB/cA and BALB/cB), after exposure to varying concentrations of cisplatin (0.1, 1 and 5 mg/kg).
Results
Cisplatin treatment induced similar responses for body and organ weights, serum analyzing factors, and blood analyzing factors in all BALB/c substrains with CT26 syngeneic tumor. Few differences were detected in the volume and histopathological structure of the CT26 tumor. Growth inhibition of CT26 tumors after exposure to cisplatin was greater in the BALB/cB substrain than BALB/cKorl and BALB/cA substrains, and a similar pattern was observed in the histopathological structure of tumors. However, the expression levels of other tumor-related factors, including Ki67, p27, p53, Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), caspase-3 (Cas-3), matrix metallopeptidase 2 (MMP2) and vascular endothelial growth factor (VEGF) proteins, were constantly maintained in the tumors of all three substrains after cisplatin treatment. A similar decrease pattern was observed for the expressions of inflammatory cytokines, including interleukin (IL)-1β, IL-6 and IL-10, in the CT26 tumors of the three BALB/c substrains.
Conclusions
Taken together, results of the present study indicate that the genetic background of the three BALB/c substrains has no major effect on the therapeutic responsiveness of cisplatin, except growth and histopathology of the CT26 syngeneic tumor.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Influence of three BALB/c substrain backgrounds on the skin tumor induction efficacy to DMBA and TPA cotreatment
- Application of Apoptogenic Pretreatment to Enhance Anti-tumor Immunity of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)-secreting CT26 Tumor Cells
- Comparison of responsiveness to cancer development and anti-cancer drug in three different C57BL/6N stocks
- The Effects of the Tumor Mass Size Inoculated in Immunologically Competent Balb/c Mice on Delayed-type Hypersensitivity Response
- Increased Anti-tumor Effect by a Combination of HSV Thymidine Kinase Suicide Gene Therapy and Interferon-gamma/GM-CSF Cytokine Gene Therapy in CT26 Tumor Model
